百勝中國(09987.HK)低開逾6% 中期純利增1.6%
百勝中國(09987.HK)低開6.15%,報348元。成交量4.99萬股,涉資1,752萬元。
百勝中國公布6月止六個月中期業績,總收入57.68億美元,按年增加2.3%。錄得純利5.07億美元,增長1.6%,每股盈利1.36美元。每股派息24美仙。單計第二季度,總收入27.87億美元,按年增加4%。純利2.15億美元,增長1.4%,每股盈利58美仙。
高盛認為,百勝中國第二季盈利表現強勁超出預期,但股價在美國交易時段仍然下跌,相信是因為在外賣平台補貼增加的背景下,市場可能正在等待第三季同店銷售增長前景出現更積極的態度,但管理層指引仍然較為審慎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.